Addex Therapeutics Reported Q3 EPS Of CHF(0.02) Up From CHF(0.03), Cash Balance Of CHF3.35M

Benzinga · Nov 22 14:14

Q3 2024 Operating Highlights:

Successfully completed funded research phase of the Indivior collaboration with both Indivior and Addex each selecting GABAB PAM drug candidate for further development in SUD and chronic cough, respectively
Completed Q3 2024 with cash and cash equivalents of CHF3.3 million

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

Addex Therapeutics Reported Q3 EPS Of CHF(0.02) Up From CHF(0.03), Cash Balance Of CHF3.35M

Risk Disclaimer